IRVINE, Calif., Oct. 29, 2012 /PRNewswire/ -- ChromaDex® Corporation (CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced today the award of two method validation study contracts from the Office of Dietary Supplements (ODS), National Institutes of Health (NIH). These awards were made as part of the contract ChromaDex has with the General Services Administration (GSA) -- Schedule 66: Scientific Equipment and Services, SIN 873-2: Chemical Testing and Analysis Services, Contract Number: GS-07F-0243W, Contract Period: March 1, 2010 to February 28, 2015.
These contracts will create single laboratory validated methods for the quantitative determination of total silymarin content of milk thistle and of total curcuminoid content in turmeric. Having analytical tools to evaluate dietary supplement identity and purity is not only required under the new Current Good Manufacturing Practices (cGMPs) from the Food and Drug Administration (FDA), but is also a critical factor for assurance of public safety, developing and maintaining quality assurance standards in manufacturing and, ultimately, for meaningful efficacy testing of these products.
ChromaDex, in addition to its own expertise, will draw on the experience and knowledge of others in the botanical and dietary supplements industry to complete these two contracts. The goal of this work is to create methods that can be used to evaluate raw materials, extracts and finished products. Once completed, the methods developed under these contracts will be published.
Commenting on the announcement, Frank Jaksch, CEO and Founder of ChromaDex, stated, "We are honored to be awarded these contracts by the NIH and ODS, as they provide further recognition of ChromaDex's phytochemical analytical expertise and the long history of collaboration between ChromaDex and the NIH in the area of dietary supplement reference standards and analytical testing. With the implementation of cGMPs now in full force, the industry needs to have robust analytical methods that they can rely on, such as the ones that will be developed by ChromaDex under the two contracts."
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Alex Partners, LLC
Scott Wilfong, President
Laura Carney, Executive Assistant
SOURCE ChromaDex Corporation